|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Maintenance therapy with rituximalo leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab,fludarabine, eyclophosphamide, and mitoxantmne ( R - FCM) in patients with recurring and refractory follicular and mantle cell lymphomas : results of a prospective randomized study of the German Low Grade Lymphoma Study Group ( GLSG ) 显示文摘 | Forstpointner R Unterhalt M Dreyling M | 2006 | Blood2006，108，13： | 1 |
| 2 | The addition of rituximab to a combination of fludarabine,cyclophosphamide,mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:results of a prospective randomized study of the german low-grade lymphoma study group显示文摘 | Forstpointner R Dreyling M Repp R | 2004 | Blood2004，104，10： | 1 |
| 3 | The addition of rituximab to a combination of fludarabine,cyclophosphamide,mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas显示文摘 | Forstpointner R Drevling M Repp R | 2004 | Blood2004，104，10： | 1 |
| 4 | Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma-follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)显示文摘 | DREYLING MH FORSTPOINTNER R LUDWIG W | 2005 | Proc Am Soc Clin Oncol2005，23，16： | 1 |
| 5 | The addition of rituximab to a combination of fludarabine, cyclophos- phamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group显示文摘 | Forstpointner R Dreyling M Repp R | 2004 | Blood2004，104，10： | 1 |
| 6 | The addition of rituximab to a combination of fludarabine,cyclophosphamide,mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group显示文摘 | Forstpointner R Hanel A Repp R | 2004 | Blood2004，104，10： | 1 |
| 7 | Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (RFCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)显示文摘 | Forstpointner R Unterhalt M Dreyling M | 2006 | Blood2006，108，13： | 1 |
| 8 | The addition of ritaximab to a combination of fudarabine,cyclophosphamide,mitoxantrone(FCM)significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:results of a prospective randomized study of the German Low-Grade Lyphoma Study Group显示文摘 | Forstpointner R Dreyling M Repp R | 2004 | Blood2004，，104： | 1 |
| 9 | The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German low grade lymphoma study group (GLSG) 显示文摘 | Forstpointner R Dreyling M Repp R | 2004 | Blood2004，104，： | 1 |
| 10 | The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group显示文摘 | FORSTPOINTNER R DREYLING M REPP R | 2004 | Blood2004，104，： | 1 |
| 11 | The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group 显示文摘 | Forstpointner R Dreyling M Repp R | 2004 | Blood2004，104，10： | 1 |
| 12 | Maintenance therapy with Rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone(R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas : Results of a prospective randomized study of the German Low Grade Lymphoma Study Group(GLSG) 显示文摘 | Forstpointner R Unterhah M Dreyling M | 2006 | Blood2006，108，： | 1 |
| 13 | The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongssurvival as compared with FCM alone in patients with relapsed and refractoryfollicular and mantle cell lympho- mas: results of a prospective randomized studyo the German Low-Grade Lymphoma Study Group 显示文摘 | Forstpointner R Dreyling M Repp R | 2004 | Blood2004，104，10： | 1 |
| 14 | The addition of rituximab to a combination of fludarabine,cyclophosphamide,mitoxantrone(FCM)significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphornas:results of a prospective randomized study of the German Low-Grade Lymphoma Study Group显示文摘 | FORSTPOINTNER R DREYLING M REPP R | 2004 | Blood2004，104，10： | 1 |
| 15 | The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM)significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymiphomas : resultes of a prospective randomized study of the German Low-Grade Lymphoma Study Group显示文摘 | FORSTPOINTNER R DREYLING M REPP R | 2004 | Blood2004，104，： | 1 |
| 16 | The addi- tion of rituximab to a combination of fludarabine, cyclo- phosphamide, mitoxantrone (FCM) significantly increa- ses the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospec- tive randomized study of the German Low-Grade Lymphoma Study Group 显示文摘 | Forstpointner R Dreyling M Repp R | 2004 | Blood2004，104，10： | 1 |
| 17 | Nine months to progression using fourth-line liposomally encapsulated paclita- xel against hepatocellular carcinoma 显示文摘 | Christopeit M Lenz G Forstpointner R | 2008 | Chemotherapy2008，54，4： | 1 |
| 18 | Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)显示文摘 | FORSTPOINTNER R UNTERHALT M DREYLING M | 2006 | Blood2006，108，13： | 1 |
| 19 | The addition of rituximab to a combination of fludarabine,cyclophosphamide,mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell ly显示文摘 | Forstpointner R Dreyling M Repp R | 2004 | {H}Blood2004，，10： | 1 |
| 20 | Maintenance therapy with rituximab leads to a significant prolongation of re- sponse duration after salvage therapy with a combination of ritux- imab, fludarabine, cyclophosphamide, and mitoxantrone (R- FCM) in patients with recurring and refractory follicular and man- tle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) 显示文摘 | Forstpointner R Unterhalt M Dreyling M | 2006 | Blood2006，108，13： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员